Impact of an oral gonadotropin‐releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained‐release gonadotropin‐releasing hormone agonist: A case report

• Published in: The journal of obstetrics and gynaecology research Vol. 47; no. 12; pp. 4472 - 4477
• Main Authors: Hanada, Tetsuro, Kimura, Fuminori, Kitazawa, Jun, Morimune, Aina, Murakami, Takashi
• Format: Journal Article
• Language: English
• Published: Kyoto, Japan John Wiley & Sons Australia, Ltd 01.12.2021; Wiley Subscription Services, Inc
• Subjects: Agonists; Breast cancer; Breast Neoplasms - drug therapy; Cancer therapies; Case reports; Chemotherapy; Delayed-Action Preparations; Endocrine therapy; Female; Fertility; Fertilization in Vitro; Freezing; Gonadotropin-Releasing Hormone; Gonadotropins; gonadotropin‐releasing hormone agonist; gonadotropin‐releasing hormone antagonist; Humans; Infertility; oncofertility; Ovarian hyperstimulation syndrome; Ovarian Hyperstimulation Syndrome - chemically induced; Ovaries; Ovulation Induction; Patients; Pituitary (anterior); ovarian hyperstimulation syndrome; breast cancer; gonadotropin-releasing hormone agonist; gonadotropin-releasing hormone antagonist; oncofertility
• ISSN: 1341-8076; 1447-0756; 1447-0756
• DOI: 10.1111/jog.15059

Postoperative hormone therapy for hormone‐sensitive patients with breast cancer is important to prevent a recurrence. As hormone therapy does not induce infertility in patients, fertility‐preserving therapy is not provided during treatment. Here, however, we performed controlled ovarian stimulation and embryo freezing for fertility preservation under the influence of a sustained‐release gonadotropin‐releasing hormone agonist in a patient with breast cancer whose postoperative treatment plan was changed from hormone therapy to chemotherapy. After oocyte retrieval, the patient developed treatment‐resistant severe symptomatic ovarian hyperstimulation syndrome. Following treatment with oral gonadotropin‐releasing hormone antagonist, her symptoms immediately improved, and she could receive chemotherapy on schedule.